Intersect
发表于 2025-3-25 05:57:42
http://reply.papertrans.cn/27/2630/262983/262983_21.png
Harass
发表于 2025-3-25 09:06:06
Richard Lai,Ajin Jirachiefpattanaarction. The primary outcome was total mortality. The trial ended nine months ahead of schedule because of clear benefit from propranolol. The independent monitoring committee considered several newly developed statistical approaches in recommending early stopping, as well as other factors, includin
陈腐的人
发表于 2025-3-25 12:18:46
http://reply.papertrans.cn/27/2630/262983/262983_23.png
caldron
发表于 2025-3-25 16:25:40
http://reply.papertrans.cn/27/2630/262983/262983_24.png
Flustered
发表于 2025-3-25 23:57:25
http://reply.papertrans.cn/27/2630/262983/262983_25.png
小丑
发表于 2025-3-26 00:20:23
https://doi.org/10.1007/978-3-030-50405-2200 mg daily) with clotrimazole lozenges (10mg, five times daily) for prevention of invasive fungal infections in patients with advanced HIV disease. At the fourth DSMB review of the study in November 1992, the patients on fluconazole had a significantly lower risk of invasive, serious and superfici
MOAT
发表于 2025-3-26 07:45:48
http://reply.papertrans.cn/27/2630/262983/262983_27.png
大厅
发表于 2025-3-26 11:25:38
Communication Rights and Social Justice91 patients with New York Heart Class II–IV heart failure and LVEF ≤0.40. The two primary objectives were to determine the effect of metoprolol CR/XL on all-cause mortality and on the combined endpoint of all-cause mortality or all-cause hospitalizations (time to first event). There was a two-week p
faddish
发表于 2025-3-26 12:51:07
Media Justice and Communication Rights of daily spironolactone to standard therapy would reduce the risk of all-cause mortality in patients with severe heart failure as a result of systolic left ventricular dysfunction. The Data Safety Monitoring Board (DSMB) for RALES reviewed data on safety and efficacy throughout the trial using pre-
鼓掌
发表于 2025-3-26 18:20:28
The Essentials of Nursing Management Seriesin the data, but also to avoid the loss of important treatment information concerning secondary outcomes, key subgroups, and patient safety data. For the Heart Outcomes Prevention Evaluation (HOPE) and Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) trials, their Data and